Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial

2020 ◽  
Vol 8 (11) ◽  
pp. 1132-1143 ◽  
Author(s):  
Yi-Long Wu ◽  
Ying Cheng ◽  
Jianying Zhou ◽  
Shun Lu ◽  
Yiping Zhang ◽  
...  
Keyword(s):  
Randomised Trial ◽  
Acquired Resistance ◽  
Small Cell ◽  
Egfr Inhibitor ◽  
Small Cell Lung ◽  
Open Label ◽  
Met Amplification ◽  
Open Label Phase ◽  
Phase 1B ◽  
Egfr Mutant

TIGER 1: A randomized, open-label, phase 2/3 study of rociletinib (CO-1686) or erlotinib as first-line treatment for EGFR-mutant non-small cell lung cancer (NSCLC).

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. TPS8108-TPS8108 ◽  
Author(s):  
D. Ross Camidge ◽  
Juergen Wolf ◽  
Jason B. Litten ◽  
Linda A Higashi ◽  
Jeffrey D. Isaacson ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Phase 2 ◽  
Small Cell Lung ◽  
First Line ◽  
Open Label ◽  
Open Label Phase ◽  
Egfr Mutant ◽  
First Line Treatment

scholarly journals ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial

2018 ◽  
Vol 19 (5) ◽  
pp. 694-704 ◽  
Author(s):  
John M Wrangle ◽  
Vamsidhar Velcheti ◽  
Manish R Patel ◽  
Elizabeth Garrett-Mayer ◽  
Elizabeth G Hill ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Open Label ◽  
Open Label Phase ◽  
Phase 1B

An open-label, phase 1b study of NEO-PV-01 with pembrolizumab plus chemotherapy in patients with advanced or metastatic nonsquamous non-small cell lung cancer.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. TPS3134-TPS3134
Author(s):  
Ramaswamy Govindan ◽  
Mark M. Awad ◽  
Lisa D Cleary ◽  
Melissa Ann Moles ◽  
Richard Gaynor ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Open Label ◽  
Open Label Phase ◽  
Phase 1B

scholarly journals BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer

2021 ◽  
Vol 14 (2) ◽  
pp. 100961
Author(s):  
Fushun Fan ◽  
Minhua Zhou ◽  
Xiaolan Ye ◽  
Zhenxian Mo ◽  
Yaru Ma ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Antitumor Activity ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Egfr Inhibitor ◽  
Small Cell Lung ◽  
Egfr Mutant
Sign in / Sign up

Export Citation Format

Share Document